Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours

por Coutelle, O, Schiffmann, L M, Liwschitz, M, Brunold, M, Goede, V, Hallek, M, Kashkar, H, Hacker, U T
Publicado 2015

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition

por Schiffmann, L M, Brunold, M, Liwschitz, M, Goede, V, Loges, S, Wroblewski, M, Quaas, A, Alakus, H, Stippel, D, Bruns, C J, Hallek, M, Kashkar, H, Hacker, U T, Coutelle, O
Publicado 2017

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

por Freeman, C L, Dixon, M, Houghton, R, Kreuzer, K-A, Fingerle-Rowson, G, Herling, M, Humphrey, K, Böttcher, S, de Costa, C S, Iglesias, V, Stilgenbauer, S, Gribben, J, Hallek, M, Goede, V
Publicado 2016

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

por Goede, V, Coutelle, O, Neuneier, J, Reinacher-Schick, A, Schnell, R, Koslowsky, T C, Weihrauch, M R, Cremer, B, Kashkar, H, Odenthal, M, Augustin, H G, Schmiegel, W, Hallek, M, Hacker, U T
Publicado 2010